Randomized Trial of Ciprofloxacin Doxycycline and Hydroxychloroquine Versus Budesonide in Active Crohn’s Disease

被引：0
|
作者：
Jonathan M. Rhodes
Sreedhar Subramanian
Paul K. Flanagan
Graham W. Horgan
Kate Martin
John Mansfield
Miles Parkes
Ailsa Hart
Helen Dallal
Tariq Iqbal
Jeffrey Butterworth
Kate Culshaw
Christopher Probert
机构：
[1] University of Liverpool,Henry Wellcome Laboratory, Department of Molecular and Clinical Cancer Medicine, Institute of Systems, Molecular and Integrative Biology, Royal Liverpool University Hospital
[2] Wirral University Teaching Hospital,undefined
[3] Biomathematics and Statistics Scotland,undefined
[4] Newcastle upon Tyne Hospitals,undefined
[5] Cambridge University Hospitals,undefined
[6] St Mark’s Hospital,undefined
[7] James Cook University Hospital,undefined
[8] Queen Elizabeth Hospital Birmingham,undefined
[9] Shrewsbury and Telford Hospital,undefined
[10] Liverpool Cancer Trials Unit,undefined
来源：
Digestive Diseases and Sciences | 2021年 / 66卷
关键词：
Crohn’s disease; Antibiotics; Ciprofloxacin; Doxycycline; Hydroxychloroquine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2700 / 2711
页数：11
相关论文
共 50 条
  • [31] The use of budesonide in the treatment of active Crohn's disease is good clinical practice
    Rutgeerts, P
    INFLAMMATORY BOWEL DISEASES, 2001, 7 (01) : 60 - 61
  • [32] Ciprofloxacin in active Crohn's disease: Preliminary report of a 6 month randomized placebo controlled study.
    Arnold, GL
    Patel, H
    Beaves, M
    Boyd, H
    GASTROENTEROLOGY, 1999, 116 (04) : A664 - A664
  • [33] Effect of food on budesonide pharmacokinetics in patients with active Crohn's disease.
    Naber, THJ
    Jansen, JBMJ
    Cvetkovic, S
    Edsbäcker, S
    Persson, T
    GASTROENTEROLOGY, 1998, 114 (04) : A1048 - A1048
  • [34] Budesonide as maintenance treatment in Crohn's disease: a placebo-controlled trial
    Hanauer, S
    Sandborn, WJ
    Persson, A
    Persson, T
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2005, 21 (04) : 363 - 371
  • [35] Budesonide versus prednisolone in the management of Crohn's disease: A randomized multi-national 2-year study
    Stockbrugger, RW
    Schoon, E
    Bollani, S
    Israeli, E
    Persson, T
    Bengtsson, B
    Persson, A
    Graffner, H
    GASTROENTEROLOGY, 2003, 124 (04) : A26 - A26
  • [36] Budesonide CIR is more effective than mesalazine in active Crohn's disease. A 16 week, international, randomized, double-blind multicentre trial
    Thomsen, OO
    Cortot, A
    Jewell, D
    Wright, JP
    Winter, T
    Veloso, FT
    Vatn, M
    Persson, T
    Pettersson, E
    GUT, 1997, 41 : A70 - A70
  • [37] Trial of helminth ova in active Crohn's disease
    Summers, RW
    Elliott, DE
    Thompson, R
    Urban, JF
    Weinstock, JV
    GASTROENTEROLOGY, 2004, 126 (04) : A75 - A75
  • [38] Budesonide for induction of remission in Crohn's disease
    Seow, Cynthia H.
    Benchimol, Eric I.
    Griffiths, Anne Marie
    Otley, Anthony R.
    Steinhart, A. Hillary
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2008, (03):
  • [39] Once versus three times daily dosing of oral budesonide for active Crohn's disease: A double-blind, double-dummy, randomised trial
    Dignass, Axel
    Stoynov, Simeon
    Dorofeyev, Andrey E.
    Grigorieva, Galina A.
    Tormova, Eva
    Altorjay, Istvan
    Tuculanu, Daniel
    Bunganic, Ivan
    Pokrotnieks, Juris
    Kupcinskas, Limas
    Dilger, Karin
    Greinwald, Roland
    Mueller, Ralph
    JOURNAL OF CROHNS & COLITIS, 2014, 8 (09): : 970 - 980
  • [40] Oral budesonide in the management of Crohn's disease
    Hofer, KN
    ANNALS OF PHARMACOTHERAPY, 2003, 37 (10) : 1457 - 1464
12345